Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
31 July 1996Website:
http://www.geron.comNext earnings report:
07 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 01 Nov 2024 23:40:42 GMTDividend
Analysts recommendations
Institutional Ownership
GERN Latest News
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 680,220 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company. The stock options were granted on October 16, 2024, at an exercise price of $4.17 per share, which is equal to the closing price of Geron common stoc.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that it will release its third quarter 2024 financial results and business highlights before the market opens on Thursday, November 7, 2024 via press release, which will be available on the Company's website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as business highlights at 8:00 a.m. ET the same day. A.
Geron's imetelstat (Rytelo) received FDA approval for MDS, marking a significant milestone despite past setbacks and negative comments from the FDA. Imetelstat, a telomerase inhibitor, shows promise in treating MDS and MF, with significant clinical trial results and manageable adverse events. Geron's financials are strong with a $2.8bn market cap and cash runway until 2026, positioning it well for future growth.
Geron (GERN) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.09 per share a year ago.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that the National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology (NCCN Guidelines) for the treatment of Myelodysplastic Syndromes (MDS) to recommend RYTELO™ (imetelstat) as a Category 1 and 2A treatment of symptomatic anemia in patients with lower-risk MDS.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 222,660 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company. The stock options were granted on June 19, 2024, at an exercise price of $4.49 per share, which is equal to the closing price of Geron common stock o.
Geron's (GERN) shares rise on approval of its first drug. The FDA approves imetelstat for the treatment of adult patients with lower-risk MDS with transfusion-dependent anemia.
The U.S. Food and Drug Administration approved Geron's lead candidate on June 6, under the brand name Rytelo. Peak Rytelo sales could surpass $1 billion annually.
Geron (GERN) shares skyrocketed over 19% in intraday trading Friday after the Food and Drug Administration (FDA) approved the biopharma company's drug Rytelo for those with rare blood cancers.
Geron (NASDAQ: GERN ) stock is heading higher on Friday after getting approval from the Food and Drug Administration (FDA) for RYTELO. RYTELO is the company's “adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent ( TD ) anemia.
- 1(current)
- 2
What type of business is Geron?
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
What sector is Geron in?
Geron is in the Healthcare sector
What industry is Geron in?
Geron is in the Biotechnology industry
What country is Geron from?
Geron is headquartered in United States
When did Geron go public?
Geron initial public offering (IPO) was on 31 July 1996
What is Geron website?
https://www.geron.com
Is Geron in the S&P 500?
No, Geron is not included in the S&P 500 index
Is Geron in the NASDAQ 100?
No, Geron is not included in the NASDAQ 100 index
Is Geron in the Dow Jones?
No, Geron is not included in the Dow Jones index
When was Geron the previous earnings report?
No data
When does Geron earnings report?
The next expected earnings date for Geron is 07 November 2024